Loading stock data…
ResMed Inc. develops (RMD)
$197.77-2.52 (-1.26%)
Market OpenUpdated 3:13 PM EDT
ResMed Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ResMed Inc. in the Healthcare sector is trading at $197.77 with a market capitalization of $28.3B. Wall Street consensus targets $260.60 (15 analysts), implying a +31.8% move over the next 12 months. The stock is currently near its 52-week low of $180.27, remaining 17.3% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +31.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.43B↑ | $1.42B↑ | $1.34B↓ | $1.35B↑ | $1.29B |
| Gross Profit | $890.98M↑ | $878.72M↑ | $820.82M | $820.07M↑ | $766.41M |
| Operating Income | $499.81M↑ | $497.60M↑ | $462.35M↑ | $456.57M↑ | $426.27M |
| Net Income | $398.73M↑ | $392.59M↑ | $348.54M↓ | $379.70M↑ | $365.04M |
Peer Comparison
JNJUNHPFE
Fundamentals
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.28B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.91%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.41%
Volume
Today's trading volume
571,150
Recent News
Are Options Traders Betting on a Big Move in ResMed Stock?
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
Is ResMed Inc. (RMD) Stock Still a Long-Term Winner as OSA Market Expansion Continues?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. ResMed Inc. (NYSE:RMD) is among the best healthcare stocks. TheFly reported on June 22 that KeyBanc adjusted its price target for RMD to $266 from $290 while maintaining an Overweight rating on the shares. The firm noted that […]
1 Oversold Stock Primed to Rebound and 2 We Find Risky
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they’re witnessing fire sales or falling knives.
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos
Check out the companies making headlines yesterday:
Why ResMed (RMD) Shares Are Falling Today
Shares of medical device company ResMed (NYSE:RMD) fell 4.5% in the afternoon session after Morgan Stanley downgraded the stock to Equalweight from Overweight and lowered its price target.